hVIVO plc Exercise of Share Options (3449C)
June 14 2019 - 7:00AM
UK Regulatory
TIDMHVO
RNS Number : 3449C
hVIVO plc
14 June 2019
HVIVO PLC
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 14 June 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that, following the exercise of employee share options by an
ex-employee, application has been made to AIM for the admission of
15,344 new ordinary shares of 5 pence each (the "New Ordinary
Shares").
Admission to trading on AIM of the New Ordinary Shares
("Admission"), which will rank pari passu in all respects with the
Company's existing shares in issue, is expected to occur on 20 June
2019.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 82,996,146 and this figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical
platform to accelerate drug discovery and development in
respiratory and infectious diseases. Leveraging human disease
models in flu, RSV and asthma exacerbation, the hVIVO platform
captures disease in motion, illuminating the entire disease life
cycle from healthy to sick and back to health. Based in the UK,
market leader hVIVO has conducted more than 50 clinical studies,
inoculated over 2500 volunteers and has three first-in-class
therapies currently in development.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOEBZLFFKQFZBBX
(END) Dow Jones Newswires
June 14, 2019 07:00 ET (11:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024